Diligence memo · auto-generated · as of July 2, 2026

Symplast Acquisition Inc.

Symplast Acquisition Inc. looks under-valued against its niche peers and is dormant on financing cadence.

DeprioritizeFinancing has gone silent well past the sector's normal cadence — treat as inactive until outside confirmation of a live operation.

Businessfiled

Symplast Acquisition Inc. operates in Other Health Care, based in PLANTATION.

No verified homepage on file yet — operating evidence is limited to the public record.

Capital & rounds (filed)filed

Symplast Acquisition Inc. has raised $7.2M in disclosed capital across 2 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).

Largest single filing: $5.0M on 2019-07-01.

Most recent recorded round closed around 2020-08-31.

Valuation (modeled)modeled

Provath models Symplast Acquisition Inc. at approximately $42M (range $2.8M–$218M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.

Read: Under-valued. Modeled value is 0.41× the median modeled value of Series A Other Health Care companies in 2019–2021 (164 peers) — value vs value, same stage and era.

Financing rhythm & timingmixed

Historic cadence: a new round about every 14 months.

Last raise 5.8 yr ago; this sector typically re-raises about every 14 months.

Silent for over 3× the sector's normal cadence.

The last round was 2.3× smaller than the prior — a bridge or down round.

Comparablesmixed

Capital scale ranks ahead of 71% of Other Health Care peers (5377 compared).

Modeled value ranks above 64% of those peers.

Closest niche peers: InvestCo Tabletop, LLC, Mediphore, Inc., iVinci Partners, LLC, Oklahoma Proton Center LLC, MicroOptx, Inc..

Peoplefiled

3 named people on file across officers, directors and signatories.

Risks & flagsmixed

Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.

No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.